Page last updated: 2024-11-13

n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide: a cannabinoid receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71711119
CHEBI ID183739
SCHEMBL ID17297543
MeSH IDM000612218

Synonyms (37)

Synonym
n-(1-adamantyl)-1-(5-luoropentyl)indazole-3-carboxamide
CHEBI:183739
1400742-13-3
n-(adamanta-1-yl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide
AKOS022172937
n-(adamantan-1-yl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide
UCMFSGVIEPXYIV-UHFFFAOYSA-N
tx64zy5p0r ,
j3.368.283b ,
n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide
dea no. 7049
1h-indazole-3-carboxamide, 1-(5-fluoropentyl)-n-tricycle(3.3.1.1sup(3,7))dec-1-yl-
5f-apinaca
apinaca n-(5-fluoropentyl)
unii-tx64zy5p0r
5f-akb-48
5-fluoro-apinaca
5f-akb48
1h-indazole-3-carboxamide, 1-(5-fluoropentyl)-n-tricyclo(3.3.1.13,7)dec-1-yl-
AKOS025212857
n-(1-adamantyl)-1-(5-fluoropentyl)indazole-3-carboxamide
SCHEMBL17297543
DTXSID80856800
1-(5-fluoropentyl)-n-tricyclo[3.3.1.13,7]dec-1-yl-1h-indazole-3-carboxamide
5-f-akb-48 (5-f-apinaca; n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide)
5f-akb-48; akb-48f; 5-f-apinaca; 5-fluoro-akb48; n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide); 1-(5-fluoropentyl)-n-tricyclo[3.3.1.1(3),?]dec-1-yl-1h-indazole-3-carboxamide
5-f-akb-48 (5-f-apinaca; n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide) 0.1 mg/ml in acetonitrile
5-f-akb-48 (5-f-apinaca; n-(1-adamantyl)-1-(5-fluoropentyl)-1h-indazole-3-carboxamide) 1.0 mg/ml in acetonitrile
BCP21130
akb-48f
Q20707142
1h-indazole-3-carboxamide, 1-(5-fluoropentyl)-n-tricyclo[3.3.1.13,7]dec-1-yl-
PD019314
mfcd22989158
5f-apinaca (5f-akb-48), 1mg/ml in methanol
5f-apinaca (5f-akb-48), 0.1mg/ml in methanol
5f-apinaca (5f-akb-48)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Abuse of SCs is dangerous because users may mistake them for natural cannabis, which is generally considered to be unlikely to elicit adverse effects."( Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity.
Bush, JM; Cabanlong, CV; Fantegrossi, WE; Fujiwara, R; Fukuda, S; Gogoi, J; Jackson, BK; McCain, K; Pinson, A; Prather, PL; Radominska-Pandya, A; Shoeib, A; Yarbrough, AL, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
indazoles
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (81.82)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (9.09%)4.05%
Observational1 (9.09%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]